| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT05856695 Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease… |
date change Primary completion pushed: 2026-02 -> 2026-11 |
| 2026-08-12 | NCT05856695 Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease… |
date change Completion pushed: 2028-02 -> 2028-11 |
| 2026-08-12 | NCT07234058 Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus… |
Recruitment opened |
| 2026-08-12 | NCT04526782 ENCOrafenib With Binimetinib in bRAF NSCLC |
date change Completion pushed: 2026-03 -> 2027-03 |
| 2026-08-11 | NCT06840834 Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose… |
date change Primary completion pushed: 2026-03-24 -> 2026-09-30 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-12 | NCT07759492 Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06908993 | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small… | Advanced Non Small Cell Lung Cancer | Recruiting |
| NCT06937905 | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced… | Neuroendocrine Carcinoma | Recruiting |
| NCT03977194 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving… | Non Small Cell Lung Cancer Metastatic | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients… | Metastatic NSCLC | Recruiting |
| Phase 2 | |||
| NCT06840834 | Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose… | Pleural Mesotheliomas | Recruiting |
| NCT06656598 | Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in… | Stage III NSCLC | Recruiting |
| NCT07234058 | Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus… | Pleural Mesotheliomas | Recruiting |
| NCT04621188 | Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC… | Non Small Cell Lung Cancer Metastatic | Active, Not Recruiting |
| NCT05200481 | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT05781308 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04526782 | ENCOrafenib With Binimetinib in bRAF NSCLC | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT05856695 | Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease… | Small Cell Lung Cancer Extensive Stage | Active, Not Recruiting |
| NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung… | Non Small Cell Lung Cancer Metastatic | Not Yet Recruiting |
| NCT07759492 | Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage III Unresectable | Not Yet Recruiting |
| Not specified | |||
| NCT06053099 | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance… | Non Small Cell Lung Cancer | Recruiting |